Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery
Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery
Subjects will be consented to the study prior to Coronary Artery Bypass Graft (CABG) and
 randomly assigned to receive either ticagrelor 90 mg bid or placebo bid starting within 48
 hours of surgery. Subjects will remain on study drug for a minimum of 12 months during which
 time they will receive telephone follow-up one and nine months following CABG and clinic
 visits three, six, and twelve months following CABG.
Patients will be screened for eligibility pre-CABG, and informed consent signed before
 randomization. Aspirin 81mg/d will be started within 12 hours of CABG as per routine
 practice. Study medication will be started within 48 hours after CABG if there are no
 contraindications. Patients will be randomized to ticagrelor 90mg bid (no loading dose) or
 placebo bid for 1 year following CABG. Aspirin 81mg/d will be continued for at least 1 year
 post-CABG. Other cardiac medications will be at the discretion of the treating physicians as
 per standard practice.

 Patients will be followed daily during their hospital stay. Outpatient visits will be
 scheduled at 3, 6 and 12 months. There will also be telephone contacts at 1 and 9 months.

 CT Substudy:Patients in the CT angiography substudy(the first 240 enrolled subjects) will
 have a cardiac CT angiogram to evaluate bypass graft patency at 3-month follow-up.Grafts will
 be separately evaluated based upon the conduits used, internal mammary, radial, or saphenous
 vein grafts. Graft patency is defined as contrast filling of the conduit and the coronary
 artery beyond the anastomosis. Grafts with ≥50% stenosis will also be recorded. The location
 of the stenosis will also be recorded (proximal anastomosis, body of graft, or distal
 anastomosis). CT angiograms will be evaluated by 2 interpreters (radiologists or
 cardiologists) blinded to the randomized treatment, and will be reviewed by a 3rd interpreter
 if there are disagreements. If no consensus could be reached among the 3 interpreters, the
 graft will be deemed not analyzable, or be subject to invasive coronary angiography for
 definitive assessment if clinically indicated.

 The primary efficacy endpoint is the composite of all-cause mortality, MI, stroke, or repeat
 revascularization within 1 year following CABG. Secondary endpoints include the individual
 endpoints of all-cause mortality, cardiovascular death, MI, stroke, repeat revascularization.
Inclusion Criteria:

 1. Males or females ≥ 19 years and ≤ 80 years old undergoing isolated CABG

 2. Females of child-bearing age must have a negative pregnancy test at enrollment

 Exclusion Criteria:

 1. Patients undergoing combined valve or aortic surgeries

 2. Patients requiring oral anticoagulant therapy on discharge that cannot be stopped
 (e.g. atrial fibrillation with CHADS2 score ≥ 2, pulmonary embolism, deep venous
 thrombosis)

 3. Known allergy or intolerance to aspirin, clopidogrel or ticagrelor

 4. Patients with active bleeding or history of bleeding diathesis

 5. Patients with previous intracranial hemorrhage at any time, or ischemic stroke within
 14 days

 6. Patients with severe liver disease (e.g. ascites or signs of coagulopathy)

 7. Patients with pre-operative or persistent post-operative Type 2 second-degree AV
 block, or 3rd degree AV block, without a permanent pacemaker

 8. Patients with end-stage renal failure requiring dialysis

 9. For patients enrolled in the CT angiography substudy, renal dysfunction with eGFR < 50
 ml/min is an exclusion criteria